A. Wells, K. Highland, S. Gläser, H. Nunes, J.W. Song, W. Wuyts, C. Stock, M. Alves, M. Padilla, on behalf of the SENSCIS trial investigators
{"title":"尼达尼布对系统性硬化症相关间质性肺疾病(SSc-ILD)患者的基线综合生理指数(CPI)影响","authors":"A. Wells, K. Highland, S. Gläser, H. Nunes, J.W. Song, W. Wuyts, C. Stock, M. Alves, M. Padilla, on behalf of the SENSCIS trial investigators","doi":"10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2433","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":131426,"journal":{"name":"B22. EMERGING MANAGEMENT OF FIBROTIC ILDs","volume":"44 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) by Composite Physiologic Index (CPI) at Baseline\",\"authors\":\"A. Wells, K. Highland, S. Gläser, H. Nunes, J.W. Song, W. Wuyts, C. Stock, M. Alves, M. Padilla, on behalf of the SENSCIS trial investigators\",\"doi\":\"10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2433\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":131426,\"journal\":{\"name\":\"B22. EMERGING MANAGEMENT OF FIBROTIC ILDs\",\"volume\":\"44 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"B22. EMERGING MANAGEMENT OF FIBROTIC ILDs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2433\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"B22. EMERGING MANAGEMENT OF FIBROTIC ILDs","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a2433","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Effect of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) by Composite Physiologic Index (CPI) at Baseline